Julie Jordan - 16 Jan 2024 Form 4 Insider Report for Neurogene Inc. (NGNE)

Role
Chief Medical Officer
Signature
/s/ Christine Mikail, as attorney-in-fact for Julie Jordan
Issuer symbol
NGNE
Transactions as of
16 Jan 2024
Net transactions value
$0
Form type
4
Filing time
18 Jan 2024, 18:48:20 UTC
Previous filing
07 Aug 2023
Next filing
28 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NGNE Stock Option (Right to Buy) Award $0 +75,000 $0.000000 75,000 16 Jan 2024 Common Stock 75,000 $32.30 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents the right to purchase 75,000 shares of common stock of the Issuer, of which 25% vests on the first anniversary of the grant date and the remainder vests in equal monthly installments through January 16, 2028, subject to the reporting person's continued service to the Issuer through each applicable vesting date.